Treatment strategy of osteoporosis (OP) is mainly based on increase in bone mineral density (BMD) and reduction of fracture risk. Bisphosphonates (BPs) are the most commonly used first-line antiresorptive agents. However, up to 30–50% of OP patients exhibit inadequate treatment response to BPs treatment, mainly due to resistance. Use of genetic markers to predict treatment response ...